Lipum AB (publ) (LIPUM.ST)
SEK 13.3
(-1.48%)
SEK 13.3
(-1.48%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 53 Thousand SEK | 0.0% |
| 2022 | - SEK | 0.0% |
| 2021 | - SEK | -100.0% |
| 2020 | 14.8 Thousand SEK | -62.1% |
| 2019 | 39.06 Thousand SEK | 1338.44% |
| 2018 | 2715.44 SEK | 16823.88% |
| 2017 | 16.05 SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | - SEK | -100.0% |
| 2024 Q3 | - SEK | 0.0% |
| 2024 Q2 | - SEK | 0.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2023 FY | 53 Thousand SEK | 0.0% |
| 2023 Q4 | 53 Thousand SEK | -53.91% |
| 2023 Q3 | 115 Thousand SEK | 0.0% |
| 2023 Q1 | - SEK | 0.0% |
| 2022 Q3 | - SEK | 0.0% |
| 2022 Q1 | - SEK | 0.0% |
| 2022 FY | - SEK | 0.0% |
| 2022 Q2 | - SEK | 0.0% |
| 2022 Q4 | - SEK | 0.0% |
| 2021 FY | - SEK | -100.0% |
| 2021 Q4 | - SEK | 0.0% |
| 2021 Q3 | - SEK | 0.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2021 Q1 | - SEK | 100.0% |
| 2020 FY | 14.8 Thousand SEK | -62.1% |
| 2020 Q4 | -197.00 SEK | -109.85% |
| 2020 Q3 | 2000.00 SEK | 0.0% |
| 2019 FY | 39.06 Thousand SEK | 1338.44% |
| 2018 FY | 2715.44 SEK | 16823.88% |
| 2017 FY | 16.05 SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 99.909% |
| Ziccum AB (publ) | 3.74 Million SEK | 98.586% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.991% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 99.895% |
| Mendus AB (publ) | 28.48 Million SEK | 99.814% |
| Genovis AB (publ.) | 158.23 Million SEK | 99.967% |
| Intervacc AB (publ) | 8.01 Million SEK | 99.339% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | 98.788% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 99.969% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 99.879% |
| Aptahem AB (publ) | 2.63 Million SEK | 97.985% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | 94.879% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 31.169% |
| Fluicell AB (publ) | 3.33 Million SEK | 98.412% |
| Saniona AB (publ) | 16.84 Million SEK | 99.685% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 99.677% |
| Biovica International AB (publ) | 7.29 Million SEK | 99.273% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | 95.594% |
| AcouSort AB (publ) | 10.55 Million SEK | 99.498% |
| Xintela AB (publ) | 78 Thousand SEK | 32.051% |
| Abliva AB (publ) | 137 Thousand SEK | 61.314% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 99.908% |
| Karolinska Development AB (publ) | 2.01 Million SEK | 97.368% |
| OncoZenge AB (publ) | 3000.00 SEK | -1666.667% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | 65.806% |
| CombiGene AB (publ) | 5.54 Million SEK | 99.044% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.996% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.997% |
| Corline Biomedical AB | 25.03 Million SEK | 99.788% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 99.067% |
| Isofol Medical AB (publ) | 721 Thousand SEK | 92.649% |
| I-Tech AB | 120.86 Million SEK | 99.956% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 99.96% |
| Cyxone AB (publ) | 5.14 Million SEK | 98.97% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 99.248% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 99.503% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 99.528% |
| Nanologica AB (publ) | 1.44 Million SEK | 96.327% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 71.46 Million SEK | 99.926% |
| Alzinova AB (publ) | 270 Thousand SEK | 80.37% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 99.85% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 96.377% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | 98.122% |
| Simris Alg AB (publ) | 4.35 Million SEK | 98.783% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | 59.231% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 99.978% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -130.435% |